Recall Classification FDA

Recall response runs on three clocks: (1) internal — from discovery to executive decision to recall; FSMA + GFSI expect ≤ 4 hours to identify all distributed inventory of an implicated lot; (2) external mandatory — Reportable Food Registry submission within 24 hours for SAHCODHA food; FDA notification 'promptly' (usually within 24 – 72 hours) for drug + device; (3) public — Enforcement Report posting weekly, press release if Class I.

• Discovery → executive notification: ≤ 1 hour (CEO, General Counsel, Head of Quality, Head of Sales, PR).
• Internal traceability close: ≤ 4 hours (every lot, every customer, every distributed quantity).
• Reportable Food Registry: 24 hours after determination of SAHCODHA reasonable probability (21 U.S.C. §350f).
• FDA notification: 'promptly'; FDA RPM defines as 'within 24 hours' for drug/device; food usually 24 – 72 hours coincident with RFR.
• Recall strategy submission: within 2 – 3 business days; FDA reviews and concurs on classification, depth, public-notification plan, effectiveness-check plan.
• Public notification (Class I): press release within 24 – 48 hours of FDA concurrence; FDA Enforcement Report posting next weekly cycle.
• Effectiveness checks: ongoing; FDA requires Levels A (100% of consignees), B (statistical sample), or C (10%) depending on hazard.

Almost all FDA recalls are voluntary — initiated by the firm in coordination with FDA. FDA strongly prefers voluntary recalls because they preserve the firm's authority over communication and execution. Mandatory recall authority exists in three places: (a) FSMA §206 (food, since 2011), (b) §518 of the FFDCA (medical devices), and (c) Bioterrorism Act for medical countermeasures. FDA invokes mandatory authority only when the firm refuses to recall voluntarily and FDA concludes the product presents a reasonable probability of serious adverse health consequences or death.

Recall depth determines how far down the distribution chain product must be retrieved. FDA classifies depth as Wholesale-Level (only direct customers), Retail-Level (stocking shelves), or Consumer-Level (already-purchased product). Class I recalls almost always require Consumer-Level depth. Depth choice is driven by where the hazard is realised: an allergen-contamination Class I is always Consumer-Level because consumption is the harm event; a packaging-quality Class III may stop at Wholesale-Level because the issue is corrected by the next handler.

Each effectiveness check is a documented contact (email, fax, phone, registered letter) confirming the consignee received the recall notice, acknowledges the product, confirms quantity on hand, and confirms the disposition path (return, destroy on-site with photo evidence, hold for inspection).

FDA terminates the recall when the firm has completed all effectiveness checks at the required level, all retrieved product has been disposed of per the strategy, and the firm has implemented corrective actions that prevent recurrence. Termination is requested in writing; FDA reviews and either terminates or asks for additional evidence. Termination is public — it appears in the Enforcement Report — and is the firm's signal to retailers and the press that the recall is complete.

• Classifying internally as Class II to soften the optics, FDA upgrades to Class I — credibility loss is permanent.
• Treating an allergen undeclaration as Class III (labeling error) when FDA classifies allergens as Class I per RPM.
• Calling a recall a 'market withdrawal' to avoid Enforcement Report listing — the second most common recall-classification Warning Letter trigger.
• Inadequate distribution traceability — cannot identify all consignees in 4 hours; missed product circulates; second recall triggered weeks later.
• Effectiveness-check level downgraded without FDA concurrence — Level B used where Level A required; FDA escalates.
• Press release language overly defensive — FDA + plaintiff's bar both read every word; admissions or evasions both hurt.
• No CAPA — recall terminated without root-cause-fixed; recurrence within 12 – 24 months; FDA classifies recurrent as systemic and escalates inspection.
• No mock-recall program — actual recall is the first time the team has ever attempted distribution reconciliation; deadlines missed.

• One-click distribution reconciliation — enter lot ID, V5 returns every WO, every finished-good pack, every consignee, every quantity, every ship date, every PO; meets GFSI 4-hour target out of the box.
• Classification decision support — guided wizard captures hazard, exposure, severity; suggests Class I / II / III with citation to 21 CFR 7.3 examples; final classification under executive e-sig.
• FDA submission package — auto-generates recall strategy per FDA RPM template, including reason, hazard, products, lot numbers, quantities, distribution pattern, public-notification draft, effectiveness-check plan.
• Reportable Food Registry submission — for food + supplements; auto-fills the §350f form from V5 distribution data; 24-hour clock visible in the workspace.
• Effectiveness-check tracker — Level A/B/C tracking per consignee; outbound notification, response, on-hand quantity, disposition path; missing-response auto-escalation.
• Disposition tracking — returned vs destroyed-on-site (with photo evidence) vs held; physical reconciliation of every unit; closes the loop on the strategy.
• Press-release + customer-letter library — pre-approved templates per class + product type; legal-review checklist; version-controlled.
• Mock-recall workflow — same engine, drill mode; quarterly drill schedule; auto-generated drill report; gap-analysis CAPA.
• CAPA + termination dossier — every recall closes with linked CAPA effectiveness check; termination package is the auditable evidence FDA wants to see before closing the file.